Santen Pharmaceutical Co (SNPHY)

OTC Markets


Symbol		Exchange		Currency
SNPHY	·	OTC Markets	·	USD	Delayed
4536	·	Frankfurt	·	EUR	Delayed
4536	·	Tokyo	·	JPY	Delayed

Currency in USD

11.63

+0.55(+4.96%)

Closed·29/07

Fair Value

Unlock Value

Day's Range

11.63

52 wk Range

8.65

13.00

SNPHY Income Statement

Featured here, the Income Statement (earnings report) for Santen Pharmaceutical Co, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Period Ending:

2016

31/03

2017

31/03

2018

31/03

2019

31/03

2020

31/03

2021

31/03

2022

31/03

2023

31/03

2024

31/03

2025

31/03

Total Revenues

aa.aa

249,605

266,257

279,037

301,965

300,004

Total Revenues Growth

aa.aa

+3.33%

+6.67%

+4.8%

+8.22%

-0.65%

Cost Of Revenues

aa.aa

98,221

109,671

112,950

123,256

128,977

Gross Profit

aa.aa

151,384

156,586

166,087

178,709

171,027

Gross Profit Growth

aa.aa

+3.18%

+3.44%

+6.07%

+7.6%

-4.3%

Gross Profit Margin %

aa.aa

60.65%

58.81%

59.52%

59.18%

57.01%

Other Operating Expenses, Total

aa.aa

97,876

120,711

130,787

126,524

122,732

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-8.41%	+23.33%	+8.35%	-3.26%	-3%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	25,416	24,103
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	113,586	120,610	134,072	87,270	83,511
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-15,710	101	-3,285	-282	1,638

Operating Income

aa.aa

53,508

35,875

35,300

52,185

48,295

Operating Income Growth

aa.aa

+34.24%

-32.95%

-1.6%

+47.83%

-7.45%

EBIT Margin %

aa.aa

21.44%

13.47%

12.65%

17.28%

16.1%

Net Interest Expenses

aa.aa

769

814

610

431

540

Net Interest Expenses Growth

aa.aa

+1.59%

+5.85%

-25.06%

-29.34%

+25.29%

Interest Expense, Total

aa.aa

-159

-249

-476

-831

-1,083

Interest And Investment Income

aa.aa

928

1,063

1,086

1,262

1,623

Other Non Operating Expenses, Total

aa.aa

-1,388

-2,192

-3,143

-7,894

981

EBT, Excl. Unusual Items

aa.aa

52,889

34,497

32,767

44,722

49,816

Gain (Loss) On Sale Of Assets

aa.aa

-102

412

-554

738

-286

Other Unusual Items, Total

aa.aa

-40,250

-93

-34,559

-8,712

-1,341

EBT, Incl. Unusual Items

aa.aa

12,418

35,616

-5,799

29,873

47,481

EBT, Incl. Unusual Items Growth

aa.aa

-61.3%

+186.81%

-116.28%

+615.14%

+58.94%

EBT, Incl. Unusual Items Margin

aa.aa

4.98%

13.38%

-2.08%

9.89%

15.83%

Income Tax Expense

aa.aa

5,773

8,427

9,184

3,171

11,628

Net Income to Company

aa.aa

6,645

27,189

-14,983

26,702

35,853

Minority Interest

aa.aa

185

-60

403

Net Income

aa.aa

6,830

27,218

-14,948

26,642

36,256

Net Income Growth

aa.aa

-71.08%

+298.51%

-154.92%

+278.23%

+36.09%

Net Income Margin %

aa.aa

2.74%

10.22%

-5.36%

8.82%

12.09%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

6,826

27,212

-14,955

26,634

36,247

Basic EPS - Continuing Operations

aa.aa

17.09

68.07

-38.6

72.59

103.98

Basic EPS - Continuing Operations Growth

aa.aa

-71.12%

+298.33%

-156.71%

+288.06%

+43.23%

Diluted EPS - Continuing Operations

aa.aa

17.06

67.97

-38.6

72.37

103.68

Diluted EPS - Continuing Operations Growth

aa.aa

-71.09%

+298.44%

-156.79%

+287.48%

+43.26%

Basic Weighted Average Shares Outstanding

aa.aa

399.46

399.78

387.42

366.89

348.61

Diluted Weighted Average Shares Outstanding

aa.aa

400.39

400.46

387.42

368.14

349.69

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

+3.7%

+14.29%

+3.13%

+9.09%

EBITDA

aa.aa

70,276

52,930

52,549

70,363

66,243

EBITDA Growth

aa.aa

+24.53%

-24.68%

-0.72%

+33.9%

-5.86%

EBITDA Margin %

aa.aa

28.15%

19.88%

18.83%

23.3%

22.08%

EBIT

aa.aa

53,508

35,875

35,300

52,185

48,295

* In Millions of JPY (except for per share items)

NSE 30

5,094.68

+35.54

+0.70%

NSE All Share

138,894.33

+981.46

+0.71%

US 30

44,664.80

+31.8

+0.07%

US 500

6,384.10

+13.2

+0.21%

FTSE 100

9,104.87

-31.45

-0.34%

DAX

24,240.78

+42.50

+0.18%

South Africa Top 40

91,620.64

+99.90

+0.11%

Market Movers

Name	Last	Chg. %	Vol.
Fidelitybk	21.300	+3.90%	77.43M
Nigerian Breweries	76.40	+3.24%	18.79M
Guaranty Trust Holding	101.40	+3.47%	14.31M
Nascon	100.00	+8.70%	11.21M
Lafarge Africa	148.00	+5.49%	7.72M
MTN Nigeria	493.50	+9.28%	4.98M
Dangote Cement	509.00	-0.12%	2.26M

Name	Last	Chg. %	Vol.
Custodian Allied	36.30	+10.00%	101.66K
Union Dicon Salt	9.90	+10.00%	61.70K
Royalex	1.54	+10.00%	13.94M
Airtel Africa	2,541.50	+10.00%	53.00
Berger Paints	37.50	+9.97%	1.79M
Guinness Nigeria	117.05	+9.96%	14.44K
UAC Of Nigeria	73.00	+9.94%	2.66M

Name	Last	Chg. %	Vol.
Total Nig	634.50	-10.00%	97.41K
Transcorp Power	288.00	-10.00%	19.63K
FTN Cocoa Processors PLC	6.30	-10.00%	9.54M
Abbey Mortgage Bank	6.89	-4.31%	415.60K
Nahco	105.300	-10.00%	2.42M
Geregu Power	1,027.40	-10.00%	2.01K
Conoil	211.10	-9.98%	4.48K

Trending Stocks

Name	Last	Chg. %	Vol.
MTN Nigeria	493.50	+9.28%	4.98M
Aradel Holdings	514.10	+0.23%	1.57M
Access Holdings	27.75	+2.02%	7.92M
VFD PLC	14.00	0.00%	5.05M
Initiates	14.20	-5.96%	3.30M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaaa A	5,398.50	+34.49%	7,260.44
Aa Aaaa Aa Aaaaa	68.00	+28.35%	87.28
Aaaaaa	500.00	+27.29%	636.45

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

Santen Pharmaceutical Co (SNPHY)

SNPHY Income Statement

Trending Stocks